Product
MEK162
7 clinical trials
8 indications
Indication
MelanomaIndication
BRAF V600 MutationIndication
Metastatic MelanomaIndication
Gastrointestinal Stromal TumorIndication
low-grade gliomaIndication
CancerIndication
BrainIndication
Soft Tissue NeoplasmsClinical trial
The LOGIC 2 Trial A Phase II, Multi-center, Open-label Study of Sequential LGX818/MEK162 Combination Followed by a Rational Combination With Targeted Agents After Progression, to Overcome Resistance in Adult Patients With Locally Advanced or Metastatic BRAF V600 Melanoma.Status: Completed, Estimated PCD: 2023-01-10
Clinical trial
A Phase Ib/II, Multicenter, Open-label, Dose Escalation Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid TumorsStatus: Completed, Estimated PCD: 2023-03-09
Clinical trial
A Phase II, Open-label Study to Assess the Safety and Efficacy of Oral MEK162 in Adults With Locally Advanced and Unresectable or Metastatic Malignant Cutaneous Melanoma, Harboring BRAFV600 or NRAS MutationsStatus: Completed, Estimated PCD: 2014-01-07
Clinical trial
A 2-part Phase III Randomized, Open Label, Multicenter Study of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients With Unresectable or Metastatic BRAF V600 Mutant MelanomaStatus: Active (not recruiting), Estimated PCD: 2016-11-09
Clinical trial
A Phase Ib/II Study of MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)Status: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
Phase I-II Study of MEK 162 for Children With Low-Grade Gliomas and Other Ras/Raf/ERK Pathway Activated TumorsStatus: Active (not recruiting), Estimated PCD: 2022-11-02